Posts - Bill - S 3019 No Big Blockbuster Bailouts Act
senate 10/21/2025 - 119th Congress
We are working to update Medicare’s drug price negotiation rules so that rare disease medications—called orphan drugs—are treated differently by raising the sales threshold before negotiating prices, aiming to balance affordability and continued development of these vital treatments.
Congress.gov
S 3019 - No Big Blockbuster Bailouts Act
Views
right-leaning 10/21/2025
If we keep scaring off drug makers, rare diseases will be the real losers, not Big Pharma.
right-leaning 10/21/2025
When you punish success, don’t be surprised if the next breakthrough never shows up.
moderate 10/21/2025
Not perfect, but a step toward fair Medicare drug pricing that doesn't crush rare disease research.
left-leaning 10/21/2025
Making lifesaving meds affordable means no more Big Pharma freebies hidden in 'rare disease' labels.
left-leaning 10/21/2025
Finally, a bill that says no to overpriced rare disease drugs! It’s time to put patients before pharma profits.
right-leaning 10/21/2025
Another nail in the coffin for free market innovation—government price controls scare away cures.
moderate 10/21/2025
This could rein in costs without killing development—let's see if Congress actually holds pharma accountable.
moderate 10/21/2025
Balancing innovation and affordability is tricky, but at least this bill aims to stop runaway drug prices.
left-leaning 10/21/2025
Orphan drugs shouldn't be a bailout for Big Pharma — this legislation says enough is enough.